{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/TNGX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-14T23:56:17.416Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2015,"canonical_name":"Tango Therapeutics, Inc.","cik":"0001819133","uei":null,"lei":null,"duns":null,"ticker":"TNGX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":51,"clinical":2},"count":53,"timeline":[{"ts":"2026-10-05","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-10-05","url_slug":"/sec/cik-0001819133/4/0001193125-26-414500","accession_number":"0001193125-26-414500","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-09-24","url_slug":"/sec/cik-0001819133/4/0001193125-26-401327","accession_number":"0001193125-26-401327","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"144","title":"144 — Tango Therapeutics, Inc. — 2026-09-22","url_slug":"/sec/cik-0001819133/144/0001950047-26-009747","accession_number":"0001950047-26-009747","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001819133/4/0001193125-26-381853","accession_number":"0001193125-26-381853","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Tango Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001819133/schedule-13g/0000886982-26-000510","accession_number":"0000886982-26-000510","importance":55},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Tango Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001819133/schedule-13g-a/0000908834-26-000425","accession_number":"0000908834-26-000425","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Tango Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001819133/schedule-13g-a/0001193125-26-352271","accession_number":"0001193125-26-352271","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Tango Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001819133/schedule-13g-a/0001916761-26-000008","accession_number":"0001916761-26-000008","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Tango Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001819133/10-q/0001193125-26-343424","accession_number":"0001193125-26-343424","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-343434","accession_number":"0001193125-26-343434","importance":35},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-344997","accession_number":"0001193125-26-344997","importance":35},{"ts":"2026-08-11","kind":"sec.filing","form_type":"424B5","title":"424B5 — Tango Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001819133/424b5/0001193125-26-344989","accession_number":"0001193125-26-344989","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"8-K/A","title":"8-K/A — Tango Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001819133/8-k-a/0001193125-26-339070","accession_number":"0001193125-26-339070","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-338480","accession_number":"0001193125-26-338480","importance":35},{"ts":"2026-08-05","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0001819133/4/0001193125-26-335002","accession_number":"0001193125-26-335002","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"144","title":"144 — Tango Therapeutics, Inc. — 2026-08-03","url_slug":"/sec/cik-0001819133/144/0001950047-26-007562","accession_number":"0001950047-26-007562","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001819133/4/0001193125-26-295124","accession_number":"0001193125-26-295124","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Crystal Adam","title":"President, R&D","shares":19629,"price_per_share":29.3424,"usd_value":575962,"security_title":"Common Stock","importance":35.5759619696},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Crystal Adam","title":"President, R&D","shares":7371,"price_per_share":30.2464,"usd_value":222946,"security_title":"Common Stock","importance":35.2229462144},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Crystal Adam","title":"President, R&D","shares":27000,"price_per_share":5.2,"usd_value":140400,"security_title":"Common Stock","importance":15.1404},{"ts":"2026-06-23","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-279788","accession_number":"0001193125-26-279788","importance":35},{"ts":"2026-06-23","kind":"sec.filing","form_type":"3","title":"3 — Azelby Robert — 2026-06-23","url_slug":"/sec/cik-0001656998/3/0001193125-26-279866","accession_number":"0001193125-26-279866","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Azelby Robert — 2026-06-23","url_slug":"/sec/cik-0001656998/4/0001193125-26-279871","accession_number":"0001193125-26-279871","importance":30},{"ts":"2026-06-19","kind":"sec.insider.a","reporter":"Azelby Robert","title":null,"shares":5740,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.form144","reporter":"Nextech Crossover I SCSp","title":"Former Affiliate","shares":3766081,"usd_value":113359038,"security_title":"Common Stock","approx_sale_date":"2026-06-17","accession_number":"0001894038-26-000002","importance":62.6718076},{"ts":"2026-06-17","kind":"sec.filing","form_type":"144","title":"144 — Tango Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001819133/144/0001894038-26-000002","accession_number":"0001894038-26-000002","importance":30},{"ts":"2026-06-11","kind":"sec.form144","reporter":"DANIELLA BECKMAN","title":"Officer","shares":1791726,"usd_value":51523582,"security_title":"Common","approx_sale_date":"2026-06-11","accession_number":"0001950047-26-005968","importance":50.304716416},{"ts":"2026-06-10","kind":"sec.form144","reporter":"DANIELLA BECKMAN","title":"Officer","shares":4446,"usd_value":133380,"security_title":"Common","approx_sale_date":"2026-06-10","accession_number":"0001950047-26-005901","importance":40.026676},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-266078","accession_number":"0001193125-26-266078","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"144","title":"144 — Beckman Daniella — 2026-06-10","url_slug":"/sec/cik-0001513422/144/0001950047-26-005901","accession_number":"0001950047-26-005901","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"424B5","title":"424B5 — Tango Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001819133/424b5/0001193125-26-266074","accession_number":"0001193125-26-266074","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"FWP","title":"FWP — Tango Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001819133/fwp/0001193125-26-264555","accession_number":"0001193125-26-264555","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-06-08","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-260679","accession_number":"0001193125-26-260679","importance":35},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-06-08","url_slug":"/sec/cik-0001819133/4/0001193125-26-262191","accession_number":"0001193125-26-262191","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-06-08","url_slug":"/sec/cik-0001819133/4/0001193125-26-262227","accession_number":"0001193125-26-262227","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"424B5","title":"424B5 — Tango Therapeutics, Inc. — 2026-06-08","url_slug":"/sec/cik-0001819133/424b5/0001193125-26-261771","accession_number":"0001193125-26-261771","importance":30},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Calhoun Lesley Ann","title":null,"shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Lee Sung","title":null,"shares":570,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Ketchum John B","title":null,"shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Rothenberg Mace","title":null,"shares":4000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-257760","accession_number":"0001193125-26-257760","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Tango Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001819133/4/0001193125-26-255940","accession_number":"0001193125-26-255940","importance":30},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Crystal Adam","title":"President, R&D","shares":20860,"price_per_share":23.0558,"usd_value":480944,"security_title":"Common Stock","importance":35.480943988},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Crystal Adam","title":"President, R&D","shares":6140,"price_per_share":22.252,"usd_value":136627,"security_title":"Common Stock","importance":35.13662728},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Crystal Adam","title":"President, R&D","shares":27000,"price_per_share":5.2,"usd_value":140400,"security_title":"Common Stock","importance":15.1404},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Tango Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001819133/schedule-13g-a/0001193125-26-226866","accession_number":"0001193125-26-226866","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Tango Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001819133/schedule-13g-a/0001916761-26-000005","accession_number":"0001916761-26-000005","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Tango Therapeutics, Inc.","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06922591","excerpt":"[\"PDAC\",\"PDAC - Pancreatic Ductal Adenocarcinoma\",\"NSCLC\",\"RAS Mutation\",\"MTAP Deletion\",\"Lung Cancer\",\"Pancreatic Cancer Metastatic\",\"Thoracic Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Tango Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001819133/10-q/0001193125-26-221656","accession_number":"0001193125-26-221656","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-221677","accession_number":"0001193125-26-221677","importance":35},{"ts":"2026-05-11","kind":"sec.13dg","reporter":"Farallon Capital Partners, L.P.","shares":11257203,"percent_of_class":7.8,"security_title":"SCHEDULE 13G/A","accession_number":"0000908834-26-000221","excerpt":null,"importance":55},{"ts":"2026-05-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Tango Therapeutics, Inc. — 2026-05-08","url_slug":"/sec/cik-0001819133/8-k/0001193125-26-213491","accession_number":"0001193125-26-213491","importance":35},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Tango Therapeutics, Inc.","title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05732831","excerpt":"[\"Locally Advanced Solid Tumor\"]","importance":45}]}